pharma Β· Asthma Β· Multiple Sclerosis Β· TEVA
Teva Pharma GmbH
Teva Pharma drug portfolio β 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 200 drugs and development assets β regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Teva Pharma drug portfolio β 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.
US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
US regulatory status: approved. Molecular target: Carbonic anhydrase 1.
US regulatory status: approved. Molecular target: Sulfonylurea receptor 1, Kir6.2.
US regulatory status: approved. Mechanism: Glutathione precursor.
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
US regulatory status: approved. Molecular target: Tumor necrosis factor.
US regulatory status: approved. Molecular target: Retinoic acid receptor.
US regulatory status: approved. Molecular target: Adenosine receptor.
Development asset linked to Teva Pharma in public FDA and regional records.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
US regulatory status: approved.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: Farnesyl pyrophosphate synthase.
Antineoplastic and immunomodulating agents (L01) compound in Teva Pharma's portfolio. Mechanism: Somatic cell supplemental therapy.
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 1B.
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
US regulatory status: approved. Molecular target: Adrenergic receptor alpha.
US regulatory status: approved. Molecular target: Mu-type opioid receptor.
US regulatory status: approved. Molecular target: Glutamate [NMDA] receptor.
Antiinfectives for systemic use (J01) compound in Teva Pharma's portfolio.
US regulatory status: approved. Molecular target: Amiloride-sensitive sodium channel, ENaC.
US regulatory status: approved. Molecular target: Voltage-gated inwardly rectifying potassium channel KCNH2.
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
US regulatory status: approved. Molecular target: Phosphodiesterase 4.
Cardiovascular system (C09) compound in Teva Pharma's portfolio. Mechanism: Voltage-gated L-type calcium channel blocker.
US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.
US regulatory status: approved. Molecular target: Dopamine receptor.
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
US regulatory status: approved. Molecular target: Aromatase.
Development asset linked to Teva Pharma in public FDA and regional records.
Genito-urinary system and sex hormones (G04) compound in Teva Pharma's portfolio. Mechanism: D2-like dopamine receptor agonist.
US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: Thioredoxin reductase 1, cytoplasmic.
US regulatory status: approved. Molecular target: Cyclooxygenase.
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
US regulatory status: approved. Molecular target: 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
US regulatory status: approved. Molecular target: Muscle-type nicotinic acetylcholine receptor.
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.
US regulatory status: approved. Molecular target: Histamine H1 receptor.
US regulatory status: approved. Molecular target: Histamine H1 receptor.
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
US regulatory status: approved. Mechanism: Diagnostic agent.
Respiratory system (R03) compound in Teva Pharma's portfolio.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
Development asset linked to Teva Pharma in public FDA and regional records. Mechanism: Angiotensin-converting enzyme inhibitor.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: Androgen receptor.
US regulatory status: approved. Molecular target: Beta-1 adrenergic receptor.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: Histamine H1 receptor.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
Development asset linked to Teva Pharma in public FDA and regional records. Molecular target: Glucocorticoid receptor.
US regulatory status: approved. Molecular target: Kappa-type opioid receptor.
Development asset linked to Teva Pharma in public FDA and regional records. Mechanism: Dopamine transporter inhibitor.
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 1A.
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
US regulatory status: approved. Mechanism: Surfactant agent.
US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
US regulatory status: approved. Molecular target: Type-1 angiotensin II receptor.
US regulatory status: approved. Molecular target: DNA.
Development asset linked to Teva Pharma in public FDA and regional records.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Mechanism: Unknown.
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-1.
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
US regulatory status: approved.
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
Development asset linked to Teva Pharma in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
US regulatory status: approved. Molecular target: Histamine H1 receptor.
US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: Ferriprotoporphyrin IX.
US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.
US regulatory status: approved. Molecular target: Histamine H1 receptor.
US regulatory status: approved. Molecular target: Sulfonylurea receptor 1, Kir6.2.
US regulatory status: approved. Molecular target: Intermediate conductance calcium-activated potassium channel protein 4.
US regulatory status: approved. Molecular target: Bile acids.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: Aluminium.
US regulatory status: approved. Molecular target: cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A.
US regulatory status: approved. Molecular target: Extracellular calcium-sensing receptor.
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
Development asset linked to Teva Pharma in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
US regulatory status: approved. Molecular target: Histamine H1 receptor.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor alpha.
US regulatory status: approved. Molecular target: Penicillin-binding protein.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
Antiinfectives for systemic use (J07) compound in Teva Pharma's portfolio. Molecular target: Spike glycoprotein.
Antiinfectives for systemic use (J07) compound in Teva Pharma's portfolio. Mechanism: Biological vaccine - induces immune response.
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 2A.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: DNA.
Blood and blood forming organs (B01) compound in Teva Pharma's portfolio. Mechanism: Thrombin inhibitor.
US regulatory status: approved. Molecular target: Prothrombin.
US regulatory status: approved. Molecular target: Peptidoglycan.
US regulatory status: approved. Molecular target: Voltage-gated potassium channel.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
US regulatory status: approved.
US regulatory status: approved. Molecular target: Histamine H1 receptor.
Development asset linked to Teva Pharma in public FDA and regional records. Mechanism: Vasopressin receptor agonist.
US regulatory status: approved. Molecular target: Vasopressin receptor.
US regulatory status: approved. Molecular target: Progesterone receptor.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
US regulatory status: approved. Molecular target: Synaptic vesicular amine transporter.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
US regulatory status: approved. Molecular target: ATP-sensitive inward rectifier potassium channel 11.
US regulatory status: approved. Molecular target: Cyclooxygenase.
US regulatory status: approved. Molecular target: Cyclooxygenase.
US regulatory status: approved. Molecular target: Cyclooxygenase.
US regulatory status: approved. Molecular target: Penicillin-binding protein.
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
US regulatory status: approved. Molecular target: Cyclooxygenase.
US regulatory status: approved. Molecular target: Sodium/potassium-transporting ATPase.
US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.
US regulatory status: approved. Molecular target: Histamine H1 receptor.
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
US regulatory status: approved. Molecular target: Succinate-semialdehyde dehydrogenase, mitochondrial.
US regulatory status: approved. Molecular target: Beta-1 adrenergic receptor.
US regulatory status: approved. Molecular target: Voltage-gated inwardly rectifying potassium channel KCNH2.
Development asset linked to Teva Pharma in public FDA and regional records. Mechanism: Acetylcholinesterase inhibitor.
US regulatory status: approved. Molecular target: Acetylcholinesterase.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-1.
Antineoplastic and immunomodulating agents (L01) compound in Teva Pharma's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
US regulatory status: approved. Molecular target: Mineralocorticoid receptor.
US regulatory status: approved. Molecular target: Adrenergic receptor.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: Steroid 5-alpha-reductase.
US regulatory status: approved. Molecular target: cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A.
US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.
US regulatory status: approved.
US regulatory status: approved.
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 1B.
US regulatory status: approved. Molecular target: Ceramide glucosyltransferase.
US regulatory status: approved. Molecular target: Thrombopoietin receptor.
Blood and blood forming organs (B03) compound in Teva Pharma's portfolio. Molecular target: Erythropoietin receptor.
US regulatory status: approved. Molecular target: Integrin alpha-IIb/beta-3.
US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
US regulatory status: approved. Molecular target: Glutamate [NMDA] receptor.
US regulatory status: approved. Molecular target: Estrogen receptor.
US regulatory status: approved. Molecular target: Estrogen receptor.
US regulatory status: approved. Molecular target: Estrogen receptor.
US regulatory status: approved. Molecular target: Estrogen receptor.
US regulatory status: approved. Molecular target: Estrogen receptor.
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
US regulatory status: approved. Molecular target: Estrogen receptor.
US regulatory status: approved. Molecular target: Voltage-gated T-type calcium channel.
US regulatory status: approved. Molecular target: Prostaglandin G/H synthase 2.
US regulatory status: approved. Molecular target: DNA topoisomerase II.
Development asset linked to Teva Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
US regulatory status: approved. Molecular target: D(1A) dopamine receptor.
US regulatory status: approved. Molecular target: Mu-type opioid receptor.
US regulatory status: approved. Molecular target: Phosphate.
Development asset linked to Teva Pharma in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.